All News

Jennie Smythe, a breast cancer survivor, shared her journey from diagnosis to survivorship in an interview with CURE during Breast Cancer Awareness Month.

A diagnosis of esophageal cancer can bring up many questions and concerns. Our goal is to provide you with clear, accurate and educational information.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Oct. 1, Previvor Day, acknowledges us who carry a hereditary cancer syndrome or genetic mutation that significantly increases our risk of cancer.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

The FDA approved the denosumab biosimilars Enoby and Xtrenbo for patients on hormone therapies for breast or prostate cancer that weaken bones.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

Heather Ann Yonker expands on strategies for maintaining food safety in the home, particularly for patients with compromised immune systems due to cancer.

Frank Garred, 77, completed Inlexzo treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates dropping to about 4% after seven years.

Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.

An LED-based intraoral device was safe and reduced severe oral mucositis and throat pain in patients receiving radiotherapy for head and neck cancers.

Tamara Mobley shares how persistent back pain led to her myeloma diagnosis and why she now raises awareness to help others recognize subtle warning signs.

Patients with prostate cancer can position themselves to receive the best care possible by being seen by a multidisciplinary team of healthcare providers.

After surviving testicular cancer, I learned to let go of envy, live in the moment, and embrace gratitude by staying true to who I am.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.

Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.

Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.

Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.

I faced breast cancer and unexpected body changes with resilience and humor, learning to adapt and find strength in the process.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Cancer during pregnancy is rare but increasingly recognized as maternal age rises and non-invasive prenatal testing becomes more common.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.

As a metastatic breast cancer patient, I want to control what I can, including my diet and exercise.

This in-depth guide offers a clear look at papillary thyroid cancer, from initial diagnosis and treatment options to long-term prognosis and living well after treatment.